Published in Clin Pharmacol Ther on February 27, 2008
Genetic Response to Warfarin in Healthy Subjects | NCT01520402
Diagnosing Adverse Drug Reactions Registry (DART) | NCT01970709
Individualized Administration of Warfarin by Polymorphisms of VKORC1 and CYP2C9 Genes | NCT03797534
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood (2008) 1.99
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther (2008) 1.90
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 1.89
Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics (2010) 1.82
Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med (2009) 1.77
Personalizing medicine with clinical pharmacogenetics. Genet Med (2011) 1.73
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials (2010) 1.72
Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. J Am Med Inform Assoc (2011) 1.67
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics (2012) 1.66
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
Warfarin pharmacogenetics. Trends Cardiovasc Med (2014) 1.57
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost (2008) 1.51
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol (2012) 1.44
Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43
The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther (2011) 1.43
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J (2011) 1.38
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics (2009) 1.37
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One (2012) 1.24
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy (2011) 1.16
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J (2013) 1.14
Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics (2010) 1.14
Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn (2009) 1.12
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics (2009) 1.09
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics (2012) 1.09
Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy (2013) 1.09
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics (2015) 1.08
Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc (2009) 1.07
Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn (2010) 1.06
Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood (2011) 1.05
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
EPMA position paper in cancer: current overview and future perspectives. EPMA J (2015) 1.04
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis (2009) 1.02
Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost (2010) 1.02
Practical Consideration of Genotype Imputation: Sample Size, Window Size, Reference Choice, and Untyped Rate. Stat Interface (2011) 1.01
Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol (2013) 0.98
Personalized medicine: challenges and opportunities for translational bioinformatics. Per Med (2013) 0.98
Information management to enable personalized medicine: stakeholder roles in building clinical decision support. BMC Med Inform Decis Mak (2009) 0.98
Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation (2012) 0.97
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol (2014) 0.97
The need for clinical decision support integrated with the electronic health record for the clinical application of whole genome sequencing information. J Pers Med (2013) 0.97
Race influences warfarin dose changes associated with genetic factors. Blood (2015) 0.96
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost (2010) 0.96
Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clin Pharmacol Ther (2014) 0.95
Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev (2009) 0.95
Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review. Iran J Pharm Res (2016) 0.95
High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. Bioinformatics (2011) 0.95
VKORC1 pharmacogenomics summary. Pharmacogenet Genomics (2010) 0.94
Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics (2012) 0.94
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J (2015) 0.94
Pharmacogenetic aspects of coumarinic oral anticoagulant therapies. Indian J Clin Biochem (2011) 0.93
Pharmacogenomics of warfarin in populations of African descent. Br J Clin Pharmacol (2013) 0.93
Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms. Eur J Clin Pharmacol (2013) 0.91
Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Clin Chem (2009) 0.90
Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One (2011) 0.90
The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet (2014) 0.90
Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med (2012) 0.89
Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther (2011) 0.89
A systems approach to designing effective clinical trials using simulations. Circulation (2012) 0.89
Pharmacogenomics discovery and implementation in genome-wide association studies era. Wiley Interdiscip Rev Syst Biol Med (2012) 0.88
Pharmacogenetics in the brazilian population. Front Pharmacol (2010) 0.88
Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol (2014) 0.88
Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics (2013) 0.87
Multivariate analysis of the relation between diet and warfarin dose. Eur J Clin Pharmacol (2011) 0.87
Paediatric models in motion: requirements for model-based decision support at the bedside. Br J Clin Pharmacol (2015) 0.87
Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers. Indian J Hum Genet (2012) 0.87
Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol (2011) 0.87
Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses. PLoS One (2014) 0.86
Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? Pharmacogenomics (2014) 0.86
A pharmacogenetics service experience for pharmacy students, residents, and fellows. Am J Pharm Educ (2013) 0.86
Population diversity and the performance of warfarin dosing algorithms. Br J Clin Pharmacol (2011) 0.86
Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells. J Thromb Haemost (2013) 0.85
Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther (2010) 0.85
Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PLoS One (2012) 0.84
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum. Korean J Intern Med (2014) 0.83
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vasc Health Risk Manag (2012) 0.83
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83
A proposed clinical decision support architecture capable of supporting whole genome sequence information. J Pers Med (2014) 0.83
VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. Eur J Clin Pharmacol (2010) 0.83
Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol (2011) 0.83
Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur J Clin Pharmacol (2008) 0.82
Warfarin pharmacogenomics in children. Pediatr Blood Cancer (2013) 0.82
The Creating an Optimal Warfarin Nomogram (CROWN) Study. Thromb Haemost (2011) 0.82
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation (2015) 0.81
A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition (1992) 16.89
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2004) 4.70
Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J (2005) 3.75
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (2007) 3.60
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet (2005) 2.97
A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med (2000) 2.73
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost (2004) 2.64
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Major bleeding after hospitalization for deep-venous thrombosis. Am J Med (1999) 2.25
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost (2005) 2.25
Managing oral anticoagulant therapy. Chest (2001) 2.25
Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood (2007) 2.23
The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost (2006) 2.04
Genetic variation analyses by Pyrosequencing. Mutat Res (2005) 1.86
Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost (2000) 1.67
Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics (2001) 1.53
Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle. J Biol Chem (2005) 1.32
Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis (2002) 1.27
Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol (2008) 1.17
Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics (2004) 1.14
Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica (2004) 1.12
Population variation in VKORC1 haplotype structure. J Thromb Haemost (2006) 1.05
Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy (2004) 1.04
Optimal initial dose adjustment of warfarin in orthopedic patients. Ann Pharmacother (2007) 1.03
Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring. J Cardiovasc Pharmacol Ther (1999) 0.98
Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther (2005) 0.98
Tailoring warfarin induction doses to reflect individual and disease-specific factors. Am J Med (2005) 0.95
A randomized trial of initial warfarin dosing based on simple clinical criteria. Thromb Haemost (2003) 0.91
A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol (1994) 30.72
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Factors associated with mortality in feedlot cattle: the Bruce County Beef Cattle Project. Can J Comp Med (1980) 7.74
Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol (2001) 7.04
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 5.54
Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA (1994) 5.38
C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation (1998) 4.80
A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci U S A (1998) 4.75
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol (1988) 4.35
Factors associated with mortality and treatment costs in feedlot calves: the Bruce County Beef Project, years 1978, 1979, 1980. Can J Comp Med (1982) 4.34
Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet (1980) 4.21
Factors associated with morbidity and mortality in feedlot calves: the Bruce County beef project, year two. Can J Comp Med (1981) 4.17
A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature (1999) 3.89
Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA (1994) 3.86
Randomised trial of personalised computer based information for cancer patients. BMJ (1999) 3.82
Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med (1995) 3.77
A prospective study of cigarette smoking and risk of cataract in men. JAMA (1992) 3.72
The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group. N Engl J Med (1989) 3.63
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med (1987) 3.34
Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther (2013) 3.29
Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. N Engl J Med (1999) 3.21
Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem (2001) 3.12
Combined management of malignant teratoma of the testis. Lancet (1979) 3.12
Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11
The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. N Engl J Med (1989) 3.11
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther (2007) 3.09
COPD prevalence in a random population survey: a matter of definition. Eur Respir J (2007) 2.97
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Risk of venous thromboembolism in users of hormone replacement therapy. Lancet (1996) 2.92
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Epidemiologic aspects of uveal melanoma. Surv Ophthalmol (1988) 2.85
Novel clinical markers of vascular wall inflammation. Circ Res (2001) 2.80
Increased pulse pressure and risk of heart failure in the elderly. JAMA (1999) 2.74
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med (2002) 2.70
Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem (2001) 2.67
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother (1996) 2.63
The primary prevention of myocardial infarction. N Engl J Med (1992) 2.63
Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med (1994) 2.62
Blood pressure and inflammation in apparently healthy men. Hypertension (2001) 2.55
Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst (1993) 2.52
Effect of marathon running on inflammatory and hemostatic markers. Am J Cardiol (2001) 2.50
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA (2001) 2.49
HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA (1995) 2.46
Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol (1999) 2.43
IMGT, the international ImMunoGeneTics database. Nucleic Acids Res (1997) 2.43
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem (1999) 2.35
A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol (1997) 2.35
Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health (1996) 2.33
Antagonist discrimination between ganglionic and ileal muscarinic receptors. Br J Pharmacol (1980) 2.31
Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med (1995) 2.31
A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA (1996) 2.27
Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes (1997) 2.26
The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun (1995) 2.25
Survival of spiral ganglion cells in profound sensorineural hearing loss: implications for cochlear implantation. Ann Otol Rhinol Laryngol (1989) 2.24
Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men. Hypertension (2000) 2.23
Practice-based research: lessons from community pharmacist participants. Pharmacotherapy (2001) 2.23
The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens (1997) 2.21
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
Relations of body fat distribution and height with cataract in men. Am J Clin Nutr (2000) 2.20
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. J Infect Dis (1996) 2.17
Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. JAMA (1995) 2.15
Localization of a small genomic region associated with elevated ACE. Am J Hum Genet (2000) 2.13
Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med (2001) 2.13
Isolation of vancomycin-resistant enterococci from animal feed in USA. Lancet (1999) 2.12
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J (2001) 2.12
The renal effects of nonsteroidal anti-inflammatory drugs in older people: findings from the Established Populations for Epidemiologic Studies of the Elderly. J Am Geriatr Soc (1999) 2.12
Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods (1996) 2.12
Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J Am Coll Cardiol (2001) 2.11
Distribution of Vibrio vulnificus in the Chesapeake Bay. Appl Environ Microbiol (1996) 2.10
Eu oxidation state in fluorozirconate-based glass ceramics. J Appl Phys (2009) 2.06
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem (2001) 2.06
Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab (2012) 2.06
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest (1999) 2.03
A research-based guideline for appropriate use of transdermal fentanyl to treat chronic pain. Oncol Nurs Forum (1998) 2.03
Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol (1998) 2.03
HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia (2007) 2.03
The place of bone-marrow transplantation in acute myelogenous leukaemia. Lancet (1980) 2.03
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest (1996) 2.02
Cloning and sequence of a region encoding a surface polysaccharide of Vibrio cholerae O139 and characterization of the insertion site in the chromosome of Vibrio cholerae O1. Mol Microbiol (1996) 2.01
Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem (2001) 2.01
Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet (2005) 2.00
Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir J (2009) 1.99
Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 1.99
The stereochemistry of the hydrogen elimination in the biological conversion of cholest-7-en-3-beta-ol into cholesterol. Biochem J (1967) 1.98
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
A systematic overview of the incidence of posterior capsule opacification. Ophthalmology (1998) 1.98
Axonal GABA-receptors in mammalian peripheral nerve trunks. Brain Res (1978) 1.97
Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med (1993) 1.97